• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于测定新型恶唑烷酮类药物DRF-6196在小鼠血浆中含量的简单生物分析方法的验证:应用于单剂量药代动力学研究

Validation of a simple bioanalytical method for the determination of DRF-6196, a novel oxazolidinone, in mouse plasma: application to a single-dose pharmacokinetic study.

作者信息

Dravid Prajakta V, Bhamidipati Ravi Kanth, Mullangi Ramesh, Srinivas Nuggehally R

机构信息

Drug Metabolism and Pharmacokinetics, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad (India).

出版信息

Arzneimittelforschung. 2005;55(4):239-44. doi: 10.1055/s-0031-1296851.

DOI:10.1055/s-0031-1296851
PMID:15901048
Abstract

An isocratic simple, specific, sensitive and reproducible high performance liquid chromatography (HPLC) method was developed and validated for the estimation of DRF-6196, a novel oxazolidinone in mouse plasma. This method involves a simple liquid/liquid extraction of DRF-6196 and the internal standard (IS; chlorzoxazone, CAS 95-25-0) from plasma into dichloromethane/ethyl acetate mixture that was evaporated under nitrogen. The HPLC analysis was carried out on an Inertsil ODS 2 column using 0.01 mol/L potassium dihydorgen ortho phosphate (pH 3.2) and acetonitrile (65:35, v/v) as mobile phase. The eluate was monitored using an UV detector set at 266 nm. Ratio of peak area of analyte to IS was used for quantification of plasma samples. The retention time of DRF-6196 and IS were 8.2 and 11.1 min, respectively. The assay was linear (r2 > 0.999) in the concentration range 0.1-50 microg/ml. Absolute recovery for analyte and IS was > 94 % from mouse plasma. The lower limit of quantification (LLOQ) of DRF-6196 was 0.1 microg/ml. The inter- and intra-day precision in the measurement of quality control (QC) samples, 0.1, 0.3, 15.0 and 40.0 microg/ml, were in the range 3.64 to 9.51 % relative standard deviation (RSD) and 0.92 to 6.23 % RSD, respectively. Accuracy in the measurement of QC samples was in the range 88.15 to 106.05 % of the nominal values. The analyte and IS were stable in the stability studies viz., benchtop, autosampler and freeze/thaw cycles. The stability of DRF-6196 was established for 1 month at -80 degrees C. The assay method was successfully applied to a pharmacokinetic study of DRF-6196 in mice.

摘要

开发并验证了一种等度洗脱的简单、特异、灵敏且可重现的高效液相色谱(HPLC)方法,用于测定小鼠血浆中的新型恶唑烷酮DRF-6196。该方法包括将DRF-6196和内标(IS;氯唑沙宗,CAS 95-25-0)从血浆中通过简单的液-液萃取至二氯甲烷/乙酸乙酯混合物中,然后在氮气下蒸发。HPLC分析在Inertsil ODS 2柱上进行,使用0.01 mol/L磷酸二氢钾(pH 3.2)和乙腈(65:35,v/v)作为流动相。使用设置在266 nm的紫外检测器监测洗脱液。分析物与内标的峰面积比用于血浆样品的定量。DRF-6196和内标的保留时间分别为8.2分钟和11.1分钟。该测定法在0.1-50μg/ml的浓度范围内呈线性(r2>0.999)。分析物和内标从小鼠血浆中的绝对回收率>94%。DRF-6196的定量下限(LLOQ)为0.1μg/ml。质量控制(QC)样品(0.1、0.3、15.0和40.0μg/ml)测定的日间和日内精密度,相对标准偏差(RSD)分别在3.64%至9.51%和0.92%至6.23%范围内。QC样品测定的准确度在标称值的88.15%至106.05%范围内。分析物和内标在稳定性研究(即台式、自动进样器和冻融循环)中稳定。DRF-6196在-80℃下的稳定性确定为1个月。该测定方法已成功应用于DRF-6196在小鼠体内的药代动力学研究。

相似文献

1
Validation of a simple bioanalytical method for the determination of DRF-6196, a novel oxazolidinone, in mouse plasma: application to a single-dose pharmacokinetic study.一种用于测定新型恶唑烷酮类药物DRF-6196在小鼠血浆中含量的简单生物分析方法的验证:应用于单剂量药代动力学研究
Arzneimittelforschung. 2005;55(4):239-44. doi: 10.1055/s-0031-1296851.
2
HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats.高效液相色谱法测定大鼠血浆中DRF-4367:方法验证及其在Wistar大鼠体内的药代动力学应用
Biomed Chromatogr. 2004 Oct;18(8):576-80. doi: 10.1002/bmc.359.
3
Quantitative determination of ragaglitazar in rat plasma by HPLC: validation and application in pharmacokinetic study.高效液相色谱法测定大鼠血浆中瑞格列他扎的含量:方法验证及其在药代动力学研究中的应用
Biomed Chromatogr. 2002 Dec;16(8):495-9. doi: 10.1002/bmc.190.
4
Validation of a simple HPLC method for DRF-4848, a novel COX-2 inhibitor suitable for pharmacokinetic application in rats.一种适用于大鼠药代动力学研究的新型COX - 2抑制剂DRF - 4848的简单高效液相色谱法的验证
Biomed Chromatogr. 2006 Dec;20(12):1289-94. doi: 10.1002/bmc.674.
5
Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies.高效液相色谱法测定大鼠血浆中的瑞舒伐他汀:方法验证及其在药代动力学研究中的应用
Biomed Chromatogr. 2006 Sep;20(9):881-7. doi: 10.1002/bmc.611.
6
Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma.基于Chiralpak手性液相色谱法测定大鼠血浆中(±)-DRF 2725对映体的方法开发与验证:血浆中瑞格列扎(S(-)-DRF 2725)未发生对映体转化。
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 25;809(1):23-30. doi: 10.1016/j.jchromb.2004.05.030.
7
Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics.采用高效液相色谱法对人血浆中DRF - 1042进行定量测定:方法验证及其在临床药代动力学中的应用
Biomed Chromatogr. 2003 Sep;17(6):385-90. doi: 10.1002/bmc.253.
8
Development and validation of an enantioselective HPLC-UV method using Chiralpak AD-H to quantify (+)- and (-)-torcetrapib enantiomers in hamster plasma--application to a pharmacokinetic study.使用Chiralpak AD-H手性柱建立并验证一种对映体选择性高效液相色谱-紫外检测法,用于测定仓鼠血浆中(+)-和(-)-托瑞米芬对映体——应用于药代动力学研究
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 1;857(2):224-30. doi: 10.1016/j.jchromb.2007.07.045. Epub 2007 Aug 6.
9
Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.采用电喷雾电离的液相色谱-串联质谱法同时测定人血浆中的瑞舒伐他汀和非诺贝特酸:方法建立、验证及临床研究应用
J Pharm Biomed Anal. 2005 Sep 15;39(3-4):661-9. doi: 10.1016/j.jpba.2005.05.005.
10
Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study.一种用于小体积人血浆样本中瑞舒伐他汀定量分析的高灵敏度、稳健的电喷雾电离液相色谱-串联质谱法的开发与验证及其在一项临床研究中的应用。
Arzneimittelforschung. 2007;57(11):705-11. doi: 10.1055/s-0031-1296671.

引用本文的文献

1
Assessment of oral bioavailability and preclinical pharmacokinetics of DRF-6196, a novel oxazolidinone analogue, in comparison to linezolid.与利奈唑胺相比,新型恶唑烷酮类似物DRF-6196的口服生物利用度及临床前药代动力学评估
Eur J Drug Metab Pharmacokinet. 2005 Jul-Sep;30(3):187-93. doi: 10.1007/BF03190619.